Trading Woche
Fresenius, DE000FRE5EN2

Fresenius stock trades flat at EUR 42.44 in weekend trading

Published on 10/10/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock costs EUR 42.44 in weekend trading on October 10, 2026 after a Xetra close of EUR 42.44. The quote is unchanged versus that close.

Key points in brief

  • Fresenius was quoted at EUR 42.44 in weekend trading at Lang & Schwarz.
  • The quote matched the EUR 42.44 close of October 9, 2026.
  • Fresenius announced full ownership of mAbxience for up to EUR 750 million.
Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht
Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock was quoted at EUR 42.44 in weekend trading at Lang & Schwarz at 10:42 a.m. CEST on October 10, 2026. The price was unchanged versus the EUR 42.44 close of the last Xetra trading day at Lang & Schwarz on October 9, 2026.

Market context: Market report DAX.

The week in figures

Lang & Schwarz showed Fresenius at EUR 42.44 in weekend trading on October 10, 2026, matching the EUR 42.44 close of October 9, 2026. The bid was EUR 42.29 and the ask was EUR 42.59.

The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Fresenius stock.

Company development

In a press release dated October 1, 2026, Fresenius said it had acquired the remaining 45 percent of mAbxience for total consideration of up to EUR 750 million, including a contingent payment of EUR 50 million upon site approvals. The transaction was signed and completed on September 30, 2026, and gave Fresenius full ownership of the biosimilars platform.

The release said no new financing was required and that the acquisition was expected to be immediately accretive to Group core earnings per share. Fresenius also said its full-year 2026 guidance and its 2030 Biopharma ambition were unchanged.

Dates of the coming week

The next Xetra session is scheduled for October 12, 2026. No company event date is stated in the reviewed Fresenius release for the coming week.

Disclaimer...

en | DE000FRE5EN2 | FRESENIUS | boerse | 70287459 | bgmi